AMRI, a global contract research and manufacturing organization, has entered into a new strategic agreement with Knopp Biosciences, a Pittsburgh-based drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.
Under the two-year term of the FTE agreement, AMRI will provide various discovery-related services that include medicinal chemistry, DMPK and computer-aided drug discovery (CADD). As part of the scope of work, AMRI scientists will collaborate with Knopp scientists and project leaders on selected novel drug discovery programs. The collaboration is extendable after two years by mutual agreement.
“We are pleased to expand our relationship with Knopp Biosciences, a company that values innovation through collaboration,” said AMRI’s Chairman, President and CEO, Thomas E. D’Ambra, Ph.D. “This agreement will combine AMRI’s broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need.”
The agreement builds on and strengthens the strategic business relationship that already exists between Knopp Biosciences and AMRI. Since 2006, AMRI has worked with Knopp to provide early process development work, route development and small-scale and large-scale cGMP manufacturing, as well as analytical method development and validation support.